Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine.
OBJECTIVE
The purpose of this study was to review the treatment outcome and safety of topical therapy with boric acid and flucytosine in women with Candida glabrata vaginitis.


METHODS
This was a retrospective review of case records of 141 women with positive vaginal cultures of C glabrata at two sites, Wayne State University School of Medicine and Ben Gurion University.


RESULTS
The boric acid regimen, 600 mg daily for 2 to 3 weeks, achieved clinical and mycologic success in 47 of 73 symptomatic women (64%) in Detroit and 27 of 38 symptomatic women (71%) in Beer Sheba. No advantage was observed in extending therapy for 14 to 21 days. Topical flucytosine cream administered nightly for 14 days was associated with a successful outcome in 27 of 30 of women (90%) whose condition had failed to respond to boric acid and azole therapy. Local side effects were uncommon with both regimens.


CONCLUSIONS
Topical boric acid and flucytosine are useful additions to therapy for women with azole-refractory C glabrata vaginitis.
Sobel
Jack D
JD
Division of Infectious Diseases, Wayne State University School of Medicine, Harper Hospital, 3990 John R, Detroit, MI 48201, USA. jsobel@intmed.wayne.edu
Chaim
Walter
W
Nagappan
Viji
V
Leaman
Deborah
D
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D001888:Boric Acids / Q000008:administration & dosage*; D041221:Candida glabrata; D002181:Candidiasis, Vulvovaginal; D005260:Female; D005437:Flucytosine / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D009824:Ointments; D019233:Retreatment; D012189:Retrospective Studies; D014627:Vaginitis / Q000382:microbiology*
D000935:Antifungal Agents; D001888:Boric Acids; D009824:Ointments; D005437:Flucytosine; C032688:boric acid